Hyperphosphatemia (disorder)
CHMP Recommends Five New Drugs and Reviews Eli Lilly’s Kisunla
CHMP; EMA; new drug approvals; Eli Lilly; Kisunla; biosimilars; hyperphosphatemia; myopia; March 2025; regulatory review
Actionable Insights Powered by AI
CHMP; EMA; new drug approvals; Eli Lilly; Kisunla; biosimilars; hyperphosphatemia; myopia; March 2025; regulatory review